Life Sciences Review

Abzena has been recognized as one of the?Top Contract Manufacturing Organization by Life Sciences Review. Abzena is a CRO and CDMO specializing in biologics and bioconjugates, offering end-to-end support from discovery to manufacturing. With proprietary technologies like ThioBridge? and AbZelectPRO?, it ensures stability, scalability, and regulatory readiness, helping biotech and pharma companies bring breakthrough therapies to market. "One thing that differentiates us as a drug development partner is that we get more involved with companies that may have a single target or a few programs in their pipeline. We understand how important these programs are to these companies, and we stay highly engaged with their leadership teams to ensure development moves along at the necessary pace for them to keep moving forward," says Matthew Stober, CEO. The article will also be featured in the forthcoming special print edition of Contract Manufacturing Organization 2025. Read More: https://lnkd.in/ghqEDGtz #Abzena #Biopharmaceuticals #DrugDevelopment #CRO #CDMO #TherapeuticInnovation #RegulatoryExcellence #Biologics #CollaborativeScience #PharmaPartnerships

PYRODEX LLC has been recognized as one of the?Top Microbiology Services Provider by Life Sciences Review. PyroDex LLC revolutionizes microbial safety testing for pharmaceuticals and medical devices with its Monocyte Activation Test (MAT), ensuring higher accuracy in detecting pyrogens—harmful contaminants that can cause severe reactions. By providing a reliable, animal-free testing method, PyroDex enhances clinical trial success rates and accelerates product commercialization, setting a new standard for drug and device safety worldwide. “Many clinical trials fail, not because of the inefficacy of the drug or flaws in the engineering design of medical devices, but due to contaminants that remain undetected by current technologies. Our method allows us to detect any pathogenic traces that could cause life-threatening conditions without relying on prior identification or knowledge of the contaminants present,” says Djikolngar Maouyo, Founder and Managing Director. The article will also be featured in the forthcoming special print edition of Microbiology 2025. Read More: https://lnkd.in/gxs5p5VH #MicrobialSafety #PharmaceuticalInnovation #MedicalDeviceTesting #PyrogenDetection #ClinicalTrialSuccess #MATTechnology #SafetyStandards #InjectableDrugs #RegulatoryCompliance #HealthcareExcellence

PBS Biotech has been recognized as the?Single Use Bioreactors Company of the Year by Life Sciences Review. PBS Biotech pioneers scalable cell therapy manufacturing with its Vertical-Wheel bioreactors, enabling high-quality production from research to commercialization. Focused on innovation and patient impact, it accelerates access to life-changing treatments. “While our primary target is drug manufacturers, the end goal is always about improving patient outcomes. We manufacture single-use bioreactors in larger volumes and faster timelines, enabling researchers to develop cell therapy products that combat chronic conditions like cancer, diabetes and heart failure,” says Brian Lee, CEO. The article will also be featured in the forthcoming special print edition of Single Use Bioreactors 2025. Read More: https://lnkd.in/dFQQjbcX #CellTherapy #Biotechnology #HealthcareInnovation #PatientOutcomes #BioreactorTechnology #ScalableSolutions #PBSBiotech #ChronicDisease #LifeSciences #TherapeuticDevelopment

Yuliya Ilieva, PhD, Head of Clinical Research at Engelhard Contributed an article "Harnessing The Potential Of Cros" “Selecting the right partners and fostering open, collaborative relationships, life sciences organizations can navigate the challenges of drug development and unlock new opportunities for growth and innovation,” says Yuliya Ilieva. The article will also be featured in the forthcoming special print edition of CRO 2025. Read More: https://lnkd.in/d8iCahbc #CROPartnerships #LifeSciences #DrugDevelopment #PharmaceuticalInnovation #ClinicalTrials #ResearchAndDevelopment #QualityAssurance #StrategicCollaboration #AgilePharma #HealthTechAdvancements

Maribelle Guloy, Director of Clinical Development at American Regent, Inc., Contributed an article "Charting A Trailblazing Path In Clinical Development" "Clinical development is the backbone of translating research into treatments. By forging pathways for pipeline advancements, we contribute to transforming healthcare with innovative treatments that address unmet patient needs and enhance lives," says Maribelle Guloy. The article will also be featured in the forthcoming special print edition of Clinical Trial 2025. Read More: https://lnkd.in/guXer7R5 #ClinicalDevelopment #HealthcareLeadership #PharmaceuticalInnovation #RegulatoryCompliance #ClinicalResearch #PatientSafety #CareerDevelopment #BiotechIndustry #HealthScience #WomenInScience

3S Pharmacological Consultation & Research has been recognized as the?CRO of the Year in Europe by Life Sciences Review. 3S Pharma is a global leader in clinical research, specializing in early-phase trials, pharmacokinetics, and bioequivalence studies. With 25+ years of expertise and state-of-the-art facilities, it ensures fast, high-quality drug development while prioritizing safety. "We’re truly customer-centered— listening, adapting and finding creative solutions to meet our clients' unique needs in the ever-evolving clinical research space," says Simona Rizea Savu, Managing Director. The article will also be featured in the forthcoming special print edition of CRO 2025. Read More: https://lnkd.in/g8AcrSFg #ClinicalResearch #PharmaceuticalInnovation #PatientSafety #DrugDevelopment #RegulatoryExcellence #HealthcareSolutions #ClinicalTrials #Biostatistics #GlobalHealth #IntegratedServices

Glow Natural Wellness has been recognized as the?Natural Beauty Supplement Company of the Year by Life Sciences Review. Glow Natural Wellness is dedicated to empowering women over 40 by supporting hormonal balance, cellular vitality, and overall well-being. Founded by naturopathic physician Dr. Michelle Sands, the company combines science and nature to create clean, cruelty-free supplements and skincare solutions. Specializing in perimenopause and menopause, Glow Natural Wellness offers products free of toxins, fillers, and synthetic ingredients—helping women feel confident, energized, and radiant at any age. “Specializing in perimenopause and menopause, I bring a potent mix of endocrinology, genetics, functional nutrition, and anti-aging expertise to the table. Every formula is crafted with care, attention, and a deep understanding of women’s health,” says Dr. Michelle Sands, ND, Founder and CEO of Glow Natural Wellness. The article will also be featured in the forthcoming special print edition of Natural Beauty Supplement 2025. Read More: https://lnkd.in/gYz7KN64 #GlowUp #WomenEmpowerment #HormonalBalance #NaturalWellness #AgeIsJustANumber #RadiantHealth #ThriveAtAnyAge #HealthyLiving #ConfidenceAtEveryStage #GlowNaturalWellness

EPS Corporation has been recognized as one of the?Top Medical Affairs Services Provider in APAC by Life Sciences Review. EPS Corporation is a leading CRO that helps international pharmaceutical and biotech companies navigate Japan’s healthcare market. Specializing in clinical research, regulatory consulting, and market access, EPS drives innovation through strategic partnerships and patient-centric solutions. "We support the development and expansion of clients’ businesses while driving value creation in the diverse pharmaceutical and medical domains," says Noriyuki Takai, Board Member, Executive Corporate Officer and Head of the Comprehensive Planning Office. The article will also be featured in the forthcoming special print edition of Medical Affairs 2025. Read More: https://lnkd.in/gvei_zGd #JapanPharmaceuticals #CRO #OncologyResearch #MarketEntry #ClinicalTrials #PharmaceuticalInnovation #RegulatoryCompliance #PatientCentricity #GlobalCollaboration #HealthcareGrowth

Antharis Therapeutics, Inc. has been recognized as the?Monoclonal Antibodies Development Company of the Year by Life Sciences Review. Antharis Therapeutics develops cutting-edge cancer treatments using monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). Founded in 2020, it focuses on precision therapies that enhance immune response while sparing healthy cells. With a robust pipeline of 56 mAbs, Antharis is redefining oncology through innovation and patient-centered care. "At Antharis Therapeutics, we are dedicated to advancing innovation in healthcare. Our cutting-edge science and robust portfolio of next-generation biotherapeutics empower us to tackle critical medical challenges and deliver therapies that may transform patient lives," says Dr. Raphael R., Chairman and CEO. The article will also be featured in the forthcoming special print edition of Monoclonal Antibodies Development 2025. Read More: https://lnkd.in/dcfsfmJW #OncologyInnovation #CancerResearch #Immunotherapy #MonoclonalAntibodies #PrecisionMedicine #Biotherapeutics #HealthcareAdvancements #CancerTreatment #ImmuneSystem #ClinicalTrials

Outcome Capital has been recognized as one of the?Top Life Sciences Investment Banking Firm by Life Sciences Review. Outcome Capital bridges science and business, guiding life sciences companies from innovation to market success. With deep expertise across biotech, pharma, and medtech, its team blends strategic insights with scientific knowledge to drive impactful transactions, mergers, and partnerships. Focused on real-world market alignment, Outcome Capital transforms groundbreaking ideas into tangible solutions, ensuring innovations reach patients and improve healthcare outcomes. "Our vision has always been to build an organization that seamlessly operates as an extension of our clients' teams, blending scientific, clinical, financial, and transactional expertise. We’ve achieved this by fostering deep collaboration, investing in top-tier talent, and consistently delivering tailored, innovative solutions that drive measurable results," says Oded Ben-Joseph, Managing Partner. "We believe the market is always right. Strategies must align with real-world needs, not just the aspirations of board members or management teams," says Arnie Freedman, Managing Partner. "Many management teams come to us with a science-focused outlook. Our role is to help them see the bigger picture—how their innovation fits into the broader market ecosystem, how to communicate its value effectively to potential investors and partners, and how to navigate the regulatory landscape," says Steven Holstein, Managing Director. The article will also be featured in the forthcoming special print edition of Life Sciences Investment Banking 2025. Read More: https://lnkd.in/gxCG-WCs #LifeSciences #Innovation #MarketStrategy #Commercialization #HealthcareImpact #Biotech #Pharmaceuticals #MedTech #StrategicPartnerships #PatientCentricity